|
RAB2A expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.42569955841054E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.1846000281277E-09 |
| Normal-vs-Stage2 |
4.06290000000142E-05 |
| Normal-vs-Stage3 |
1.01340003055839E-09 |
| Normal-vs-Stage4 |
1.05929999993926E-07 |
| Stage1-vs-Stage2 |
9.214400E-01 |
| Stage1-vs-Stage3 |
2.197400E-01 |
| Stage1-vs-Stage4 |
2.578000E-01 |
| Stage2-vs-Stage3 |
3.672200E-01 |
| Stage2-vs-Stage4 |
3.599400E-01 |
| Stage3-vs-Stage4 |
8.455400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.96750402029033E-11 |
| Normal-vs-AfricanAmerican |
9.342200E-02 |
| Normal-vs-Asian |
8.48450000034973E-07 |
| Caucasian-vs-AfricanAmerican |
8.136300E-03 |
| Caucasian-vs-Asian |
9.649800E-01 |
| AfricanAmerican-vs-Asian |
2.991800E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.21609952610891E-10 |
| Normal-vs-Female |
2.68190003538393E-09 |
| Male-vs-Female |
9.485900E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
7.15119999883385E-08 |
| Normal-vs-Age(41-60Yrs) |
3.73040043299966E-10 |
| Normal-vs-Age(61-80Yrs) |
1.12020000053725E-07 |
| Normal-vs-Age(81-100Yrs) |
2.742500E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.426800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.798000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.528800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.499600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.997600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.119200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.578640E-01 |
| Classical-VS-Follicular |
3.296800E-01 |
| Classical-VS-Other |
3.391000E-01 |
| Classical-VS-Normal |
9.40650002334564E-09 |
| Tall-VS-Follicular |
6.963400E-01 |
| Tall-VS-Other |
5.829200E-01 |
| Tall-VS-Normal |
8.56920000513739E-08 |
| Follicular-VS-Other |
5.869600E-01 |
| Follicular-VS-Normal |
3.50169999996375E-07 |
| Other-VS-Normal |
3.175500E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.06270003907838E-09 |
| Normal-vs-N1 |
2.18419999975517E-07 |
| N0-vs-N1 |
4.676600E-01 |
|
|
